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Abstract
Background: Gonorrhoea is a sexually transmitted infection caused by the Gram-negative bacterium Neisseria
gonorrhoeae. Resistance to first-line empirical monotherapy has emerged, so robust methods are needed to
evaluate the activity of existing and novel antimicrobials against the bacterium. Pharmacodynamic models
describing the relationship between the concentration of antimicrobials and the minimum growth rate of the
bacteria provide more detailed information than the MIC only.
Results: In this study, a novel standardised in vitro time-kill curve assay was developed. The assay was validated
using five World Health Organization N. gonorrhoeae reference strains and a range of ciprofloxacin concentrations
below and above the MIC. Then the activity of nine antimicrobials with different target mechanisms was examined
against a highly antimicrobial susceptible clinical strain isolated in 1964. The experimental time-kill curves were
analysed and quantified with a previously established pharmacodynamic model. First, the bacterial growth rates at
each antimicrobial concentration were estimated with linear regression. Second, we fitted the model to the growth
rates, resulting in four parameters that describe the pharmacodynamic properties of each antimicrobial. A gradual
decrease of bactericidal effects from ciprofloxacin to spectinomycin and gentamicin was found. The beta-lactams
ceftriaxone, cefixime and benzylpenicillin showed bactericidal and time-dependent properties. Chloramphenicol
and tetracycline were purely bacteriostatic as they fully inhibited the growth but did not kill the bacteria. We also
tested ciprofloxacin resistant strains and found higher pharmacodynamic MICs (zMIC) in the resistant strains and
attenuated bactericidal effects at concentrations above the zMIC.
Conclusions: N. gonorrhoeae time-kill curve experiments analysed with a pharmacodynamic model have potential
for in vitro evaluation of new and existing antimicrobials. The pharmacodynamic parameters based on a wide
range of concentrations below and above the MIC provide information that could support improving future dosing
strategies to treat gonorrhoea.
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Background
Antimicrobial resistance in Neisseria gonorrhoeae is a major
public health problem. Strains that have developed resist-
ance to all antimicrobials used for treatment have been
classified as superbugs [1–3]. Clinical resistance to the last
option for empirical antimicrobial monotherapy, ceftriax-
one, was first described in 2009 [4]. Currently, treatment
recommendations for gonorrhoea and prediction of the
efficacy of antimicrobials mainly rely on a single measure-
ment: the MIC of the antimicrobial, sometimes supported
by data from old clinical trials and pharmacokinetic/phar-
macodynamic (PK/PD) simulations. However, antimicro-
bials that have different modes of action and lead to
different treatment outcomes can have identical MICs [5].
A better understanding of the in vitro pharmacodynamic
properties of antimicrobials could be used to optimise dos-
ing strategies and help prevent treatment failures [6].
Time-kill curves that monitor bacterial growth and
death over a wide range of antimicrobial concentrations
have been frequently used to evaluate the effect of antimi-
crobials over time. These data can be analysed using
mathematical models and are often the first step in PK/
PD modelling. Regoes et al. [7] analysed time-kill curves
from E. coli exposed to different classes of antimicrobials
using a pharmacodynamic model that is characterised by
four parameters: the maximal bacterial growth rate in the
absence of antimicrobial (ψmax), the minimal bacterial
growth rate at high concentrations of antimicrobial (ψmin),
the Hill coefficient (к), and the pharmacodynamic MIC
(zMIC) (Fig. 1). This model, which is closely related to
Emax models [5], has also been applied to study the effects
of antibiotics alone and in combinations against other
pathogens, such as Staphylococcus aureus [8] and Myco-
bacterium marinum [9].
Information about the effects of antimicrobials covering
a wide range of antimicrobial concentrations below and
above the MIC is particularly valuable for pathogens like
N. gonorrhoeae, because data about PK/PD effects are
limited. There is no standardised and quality assured
time-kill curve analysis or animal model for the fastidious
obligate human pathogen N. gonorrhoeae. Most published
time-kill protocols for N. gonorrhoeae [10–12] are not
generalizable, owing to the highly divergent growth
requirements of different strains and interpretation of re-
sults generally relies on qualitative expert judgement. To
study a wide range of N. gonorrhoeae strains, growth in
absence of antimicrobials must be consistent and bacterial
growth phases at the time of exposure to antimicrobial
need to be synchronised in early to mid-log phase.
In this study, a standardised in vitro time-kill curve
assay for N. gonorrhoeae was developed using Graver-
Wade (GW) medium. GW medium is a chemically
defined, nutritious, liquid medium that supports growth
of a wide range of N. gonorrhoeae auxotypes and clinical
Fig. 1 Pharmacodynamic model with four parameters. The bacterial growth rates (ψ) in response to each antimicrobial concentration are estimated from
time-kill data with linear regression. The maximal bacterial growth rate ψmax, the minimal bacterial growth rate at high concentrations of antimicrobial ψmin,
the pharmacodynamic MIC (zMIC) and the Hill coefficient к are shown and define the shape of the curve
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isolates starting from very low inocula [13]. The novel
time-kill curve assay was validated on five World Health
Organization N. gonorrhoeae reference strains with fluoro-
quinolone resistance determinants. A highly susceptible
clinical N. gonorrhoeae isolate (DG666, isolated in 1964)
was subsequently studied in detail and time-kill curve
experiments performed for nine antimicrobials that have
been, or currently are, used to treat gonorrhoea. In a
second step we analysed the time-kill data using a phar-
macodynamic model [7] for a comparative analysis of the
pharmacodynamic properties of different antimicrobials.
Methods
Neisseria gonorrhoeae isolates and media
The five international N. gonorrhoeae reference strains
WHO G, WHO K, WHO L, WHO M, and WHO N with
different ciprofloxacin conferring mutations in gyrA, parC
and parE [14, 15] and a clinical isolate susceptible to all an-
timicrobials that were examined (wild type) cultured in
1964 (DG666), were studied. Isolates were cultured, from
frozen stocks (−70 °C), on GCAGP agar plates (3.6 % Difco
GC Medium Base agar [BD, Diagnostics, Sparks, MD,
USA] supplemented with 1 % haemoglobin [BD, Diagnos-
tics], 1 % IsoVitalex [BD, Diagnostics] and 10 % horse
serum) for 18–20 h at 37 °C in a humid 5 % CO2-enriched
atmosphere. Gonococcal colonies were subcultured once
more on GCAGP agar for 18–20 h at 37 °C in a humid 5 %
CO2-enriched atmosphere, before being transferred to the
liquid sterile GW medium, prepared as earlier described
[13], for growth curve and time-kill experiments.
Viable cell counts
Bacterial viability was measured using a modified Miles
and Misra method as previously described [16]. Growing
bacteria were removed from 96-well plates at specified
time points using a multichannel pipette and diluted in
sterile phosphate buffered saline (PBS) in six subsequent
1:10 dilutions (20 μl culture in 180 μl diluent). Ten μl
droplets of each dilution were spotted on GCRAP (3.6 %
Difco GC Medium Base agar [BD, Diagnostics] supple-
mented with 1 % haemoglobin [BD, Diagnostics] and 1 %
IsoVitalex [BD, Diagnostics]). GCRAP plates were dried
with the lid open in a sterile environment for 30–60 min
before use. After drying the droplets (approximately 5–10
min), plates were incubated for 24 h at 37 °C in a humid
5 % CO2-enriched atmosphere. For every concentration
and time point, colonies were counted for the first dilution
that resulted in a countable range of 3–30 colonies and
the CFU/ml calculated.
Growth curves
Prior to growth curve experiments, strains were subcul-
tured once on chocolate agar PolyViteX (Biomerieux). A
0.5 McFarland inoculum was prepared and diluted to
100 CFU/ml (1:106) in GW Medium (35 °C). A volume
of 100 μl diluted bacteria per well was transferred to Sar-
stedt round-bottom 96 well plates. The plates were
tightly sealed with adhesive polyester foil (Sarstedt) and
bacteria were grown shaking at 100 rpm at 35 °C in a
humid 5 % CO2-enriched atmosphere. Bacterial growth
was monitored over a time-course of 60 h (0, 2, 4, 6, 8,
10, 12, 20, 22, 24, 26, 28, 30, 32, 34, 40, 44, 48, 60 h).
For every sampled time point, the content of one well
was removed and viable counts determined [16]. Growth
curves were analysed by plotting the log CFU/ml against
the time and fitting a Gompertz growth model [17] to
the data as implemented in the package cellGrowth [18]
for the R software environment for statistical computing
[19]. Only lag, log and stationary phases were included
in the analysis and the decline phase excluded.
Time-kill assay
Time-kill curve analyses were performed by culturing
N. gonorrhoeae in GW medium [13], in the presence
of 11 antimicrobial concentrations in doubling dilu-
tions ranging from 0.016 ×MIC to 16 ×MIC. For
DG666, the MICs were determined before the experi-
ment using Etest (bioMérieux, Marcy l’Etoile, France)
according to the manufacturer’s instructions. For all
other strains, previously published MIC values were
used [14]. The antimicrobials examined were cipro-
floxacin (Sigma Aldrich, China), gentamicin (Sigma
Aldrich, Israel), spectinomycin (Sigma Aldrich, Israel),
azithromycin (Sigma Aldrich, USA), benzylpenicillin
(Sigma Aldrich, USA), ceftriaxone (Sigma Aldrich,
Israel), cefixime (European pharmacopeia reference
standard, France), chloramphenicol (Sigma Aldrich,
China) and tetracycline (Sigma Aldrich, China).
Growth curves were initially performed to confirm
that all strains would reach a stable early- to mid-log
phase after 4 h of pre-incubation in antimicrobial-free
GW medium. A 0.5 McFarland inoculum of N. gonor-
rhoeae was then prepared in sterile PBS from cultures
grown on GCAGP agar plates for 18–20 h at 37 °C
in a humid 5 % CO2-enriched atmosphere. For each
strain, 30 μl of the inoculum was diluted in 15 ml
pre-warmed (37 °C) antimicrobial-free GW medium
and 90 μl per well was dispersed in round bottom
96-well Sarstedt microtiter plates. The plates were
pre-incubated for 4 h shaking at 150 rpm, 35 °C in a
humid 5 % CO2-enriched atmosphere. To each well
containing 90 μl of pre-incubated bacteria, 10 μl of
one of the antimicrobial concentrations (or PBS) was
added, resulting in eight identical rows (one row for
each time-point) containing bacteria exposed to 11
different antimicrobial concentrations and one un-
treated control.
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Estimating bacterial growth rates
The bacterial growth rates (ψ) were determined from
changes in the density of viable bacteria (CFU/ml) during
the first 6 h of the time-kill experiments. The bacterial
populations were assumed to grow or die at a constant
rate, resulting in an exponential increase or decrease in
bacterial density:
N tð Þ ¼ N0  eψt :
The growth rate was estimated as the coefficient of a
linear regression from the logarithm of the colony
counts. Maximum likelihood estimation was used to ac-
count for the censored data (values below the limit of
detection of 100 CFU/ml). For a given antimicrobial, the
geometric mean of all measurements at zero hours was
used as the first data point. From the growth rate, the
bacterial doubling time can be calculated as follows:
T1=2 ¼ ln 2ð Þψ :
Pharmacodynamic model
The pharmacodynamic model by Regoes et al. [7] describes
the relationship between bacterial growth rates (ψ) and the
concentration of an antimicrobial (a) (Fig. 1):
ψ að Þ ¼ ψmax−
ψmax−ψminð Þ azMIC
 κ
a
zMIC
 κ− ψminψmax
;
where ψmax is to the maximal bacterial growth rate in
the absence of antimicrobial and ψmin is the minimal
bacterial growth rate at high concentrations of anti-
microbial. zMIC is the pharmacodynamic MIC where
the bacterial growth rate is zero (ψ(zMIC) = 0). к denotes
the Hill coefficient, which describes the steepness of the
sigmoid relationship between bacterial growth and anti-
microbial concentration. For each antimicrobial, four
parameters of the pharmacodynamic model were esti-
mated using a self-starter function, implemented in the
R software package drc [20]. All figures can be repro-
duced with R code and data from a publicly available
GitHub repository [21].
Results
Growth of N. gonorrhoeae
Growth curves for the five different WHO N. gonorrhoeae
reference strains (Additional file 1: Figure S1) confirmed
that growth was well supported in GW medium. All
strains could be grown from a starting inoculum of fewer
than 103 CFU/ml and typically had a lag phase of under 4
h. The stationary phase lasted until 36 h for all strains,
followed by a steep decline phase. Growth was similar for
all strains, with WHO L the only strain that had a slightly
longer lag phase (4 h).
Time-kill curves
Time-kill curves for ciprofloxacin using the WHO refer-
ence strains WHO G (MIC = 0.125 μg/ml), WHO K
(MIC > 32 μg/ml), WHO L (MIC > 32 μg/ml), WHO M
(MIC = 2 μg/ml), WHO N (MIC = 4 μg/ml) and DG666
(MIC = 0.008 μg/ml) are shown in Fig. 2. Ciprofloxacin
induced a bactericidal effect in all six strains, but the on-
set of the bactericidal activity was dependent on the con-
centration of the antimicrobial and differed between
strains. All strains with the exception of WHO M and
WHO N were killed to below the limit of detection
(100 CFU/mL) at the highest antimicrobial concentra-
tion (16 fold MIC). The susceptible DG666 strain experi-
enced the most rapid killing during the first hour at high
antimicrobial concentrations. For WHO G and WHO
M, the bactericidal activity decreased during the 6 h of
the assay.
Time-kill curves for eight additional antimicrobials were
also made (spectinomycin, gentamicin, azithromycin, ben-
zylpenicillin, ceftriaxone, cefixime, chloramphenicol and
tetracycline) using the highly antimicrobial susceptible
DG666 strain (Fig. 3). Similar to the effect of ciprofloxacin
(Fig. 2f), gentamicin and spectinomycin exhibited rapid
killing during the first 2 h of the assay for concentrations
above MIC. Cefixime and ceftriaxone showed little effect
from zero to 3 h but the growth rate then decreased rap-
idly. For benzylpenicillin and azithromycin, at concentra-
tions above MIC, the killing started after 1 h and decreased
rapidly at later time points. The time-kill curves for tetra-
cycline and chloramphenicol looked similar with almost no
killing of bacteria within the assay time of 4 h. Chloram-
phenicol showed a weak bactericidal effect at the highest
antimicrobial concentration (Fig. 3).
Pharmacodynamic model
The bacterial growth rates were estimated from the
time-kill curves by fitting a linear regression to the loga-
rithm of the colony counts (Fig. 4a). The pharmacody-
namic model was then fitted to the estimated growth
rates at different antimicrobial concentrations (Fig. 4b,
solid line). In most of the cases exposure to high anti-
microbial concentrations (above 16 fold zMIC) resulted
in a lower asymptote of the model (ψmin) and higher
concentrations had no additional effect on the growth
rate. For chloramphenicol, ceftriaxone, cefixime and
benzylpenicillin the growth rate dropped again at very
high antimicrobial concentrations. The Hill function
could not be fitted appropriately in these cases (Fig. 4b,
dashed line), therefore these data points were removed
before estimating the parameters of the pharmacody-
namic model. However, this phenomenon might indicate
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distinct biological effects on bacterial growth at different
antimicrobial concentrations (see Discussion).
Strains with resistance determinants to ciprofloxacin
resulted in significantly changed pharmacodynamic pa-
rameters (Fig. 4c and Additional file 1: Table S2). The
DG666 strain had a low pharmacodynamic MIC (zMIC)
and a low minimal growth rate (ψmin), indicating the
strong bactericidal effect of ciprofloxacin. The five
WHO reference strains showed that the ciprofloxacin
resistance determinants shifted the zMIC to higher
values and resulted in an increase of the minimal growth
rate (ψmin) compared to DG666 strain.
The pharmacodynamic parameters for the nine anti-
microbials in the DG666 strain illustrated the different
effects that antimicrobials have on the growth of N.
gonorrhoeae (Fig. 4d and Table 1). The average of the
maximal growth rate in the absence of antimicrobials
over all experiments was ψmax = 0.77 h
−1 (95 % confi-
dence interval [CI]: 0.71-0.84 h−1). This corresponds to a
bacterial doubling time of T1/2 = 54 min (95 % CI: 49–
59 min). Ciprofloxacin, spectinomycin and gentamicin
induced the strongest bactericidal effect with ψmin < −5 h
−1. Chloramphenicol and tetracycline exhibited almost
no killing within the 6 h of the assay (ψmin > −0.2 h
−1).
The Hill coefficient к ranged between 1.0 and 2.5. The
pharmacodynamic parameters were similar for ceftriax-
one, cefixime and the bacteriostatic compounds chlor-
amphenicol and tetracycline. Generally, the estimated
zMIC agreed well with the MIC measured by Etest
(within one doubling dilution) but were lower for ben-
zylpenicillin, ceftriaxone, cefixime and gentamicin.
Discussion
A robust and reliable method to evaluate antimicrobial
treatment options in vitro is urgently needed to help tackle
the problem of antimicrobial resistant N. gonorrhoeae. In
this study, a standardised in vitro time-kill curve assay was
developed and the resulting data were analysed using a
pharmacodynamic model that describes the relationship be-
tween the concentration of antimicrobials and the bacterial
growth rate [7]. We obtain and compare in vitro pharmaco-
dynamic parameters of antimicrobials in susceptible and re-
sistant strains of the same pathogenic species, opening up
avenues into understanding the effects of different resist-
ance determinants on strain phenotype.
The time-kill assay we developed worked well for dif-
ferent N. gonorrhoeae strains, including highly resistant
isolates. Time-kill assays are usually very laborious but
growing the bacteria in 96-microwell plates and using the
modified Miles and Misra method [16] for plating made it
possible to study 12 antimicrobial concentrations in the
same experiment. The assay time was limited to 6 h and
growth in the absence of antimicrobials was highly con-
sistent and exponential for all strains during that time.
The analysis of time-kill data for the susceptible strain
DG666 showed strong bactericidal effects of ciprofloxacin,
gentamicin and spectinomycin. Ciprofloxacin is a prime
example of a bactericidal antimicrobial, representing the
class of topoisomerase II inhibiting fluoroquinolones [22].
The five WHO reference strains used in this study have
different ciprofloxacin resistance-conferring mutations in
gyrA, parC and parE. This was reflected in an increased
pharmacodynamic MIC (zMIC) and a weaker bactericidal
effect of ciprofloxacin, showing that even exposure to high
concentrations (16 fold MIC) had a limited effect on the
growth of these resistant strains.
Spectinomycin and gentamicin both inhibit protein
translation [23–25]. Spectinomycin is a well-recognised
treatment option for gonorrhoea and resistance is found
rarely [26, 27]. Gentamicin is currently the recom-
mended first-line treatment for gonorrhoea in Malawi,
where it is used together with doxycycline in the syn-
dromic management of urethritis [28]. This aminoglyco-
side has been suggested for wider use in the treatment
of gonorrhoea recently [29–31] and our time-kill data
suggest that further exploration of this treatment option
could be rewarding.
The cell wall inhibiting β-lactam antimicrobials are
known to have a time-dependent mode of action [32, 33].
Therefore it was not surprising that benzylpenicillin, cef-
triaxone and cefixime were characterised by time-
dependent, bactericidal killing (−1.6 h−1 < ψmin < 0.6 h
−1).
Although currently not used for treatment of N. gonor-
rhoeae, chloramphenicol and tetracycline often act as
model compounds for bacteriostatic effects [34, 35]. These
effects were confirmed by growth rates close to zero at
high antimicrobial concentrations (ψmin). Resistance to
tetracycline is widespread [36] and chloramphenicol is
relatively toxic and has undesirable side effects [37], so
neither of these antimicrobials is currently routinely used
for the treatment of gonorrhoea.
The Hill coefficient k describes the steepness of the
pharmacodynamic curve around the zMIC. Higher values
of k result in a steeper curve and a more dramatic increase
in bacterial killing for increasing antimicrobial concentra-
tions. For low values of k, increasing antimicrobial
(See figure on previous page.)
Fig. 2 Time-kill curves for ciprofloxacin and six different Neisseria gonorrhoeae strains. Time-kill curves for WHO G (a), WHO K (b), WHO L (c), WHO M (d),
WHO N (e) and DG666 (f) are shown. Twelve doubling dilutions are plotted, the highest concentration (black line) corresponds to 16× MIC as measured
with Etest and growth in absence of antimicrobial is drawn in red. The antimicrobial was added at timepoint 0 and monitored until 6 h. The limit of
detection in the assay was 100 CFU/ml
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(See figure on previous page.)Fig. 3 Time-kill curves for the Neisseria gonorrhoeae DG666 strain using eight different antimicrobials. The
antimicrobial susceptible strain DG666 was exposed to the antimicrobials gentamicin (a), spectinomycin (b), azithromycin (c), benzylpenicillin (d),
ceftriaxone (e), cefixime (f), chloramphenicol (g) and tetracycline (h). Twelve doubling dilutions are plotted, the highest concentration (black line)
corresponds to 16× MIC as measured with Etest and growth in absence of antimicrobial is drawn in red. The antimicrobial was added at
timepoint 0 and monitored until 6 h. The limit of detection in the assay was 100 CFU/ml. Data from one of two independent experiments are
shown. Additional data are available on GitHub [21]
a b
c d
Fig. 4 Pharmacodynamic functions for different antimicrobials and Neisseria gonorrhoeae strains. a Estimating growth rates (cefixime in DG666). Dashed
lines represent linear regressions of the logarithm of the colony counts at different antimicrobial concentrations. The coefficient of the linear regression
corresponds to the net bacterial growth rate. b Fitting the pharmacodynamic function to estimated growth rates (cefixime in DG666). Points correspond
to the estimated net bacterial growth rates at different antimicrobial concentrations. The solid line shows the model fit excluding the estimated net
bacterial growth rates at very high antimicrobial concentrations. The dashed line indicates the model fit including all data points. The growth rate in
absence of antimicrobial is shown in red at a concentration that is 10-fold lower than the lowest concentration. c Pharmacodynamics functions for
ciprofloxacin in six N. gonorrhoeae strains (Low Level Resistance (LLR) =WHO G; High Level Resistance (HLR) =WHO K, WHO L; Resistance (R) =WHO M,
WHO N; and Susceptible (S) = DG666). d Pharmacodynamic functions for nine different antimicrobials in DG666 strain. Note that each curve is based on
the arithmetic mean of the estimated parameters from two independent time-kill experiments (as in Table 1)
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concentrations result in only marginal increases in bacter-
ial killing, suggesting that the time above the zMIC may
be a more important correlate for efficacy than a high ra-
tio of maximum concentration to zMIC. Hence, Regoes et
al. [7] hypothesised that high and low Hill coefficients are
associated with concentration- and time-dependent anti-
microbials such as ciprofloxacin and tetracycline,
respectively. In our study, we did not find significantly
different Hill coefficients for ciprofloxacin and the time-
dependent beta-lactams. However time-dependent antimi-
crobials were clearly associated with higher minimal
growth rates (ψmin) in our data. These results are in line
with a review of pharmacodynamic parameters from
different organisms and antibiotics. Czock and Keller [38]
found a lower maximum kill rate for time-dependent
compared to concentration-dependent antimicrobials.
The association with time-dependency was less clear for
the Hill coefficient and further studies were suggested to
confirm a tendency towards higher values in some of the
studies [38]. The Hill coefficient (к) might also depend on
the genetic background and metabolism of different
strains therefore isogenic strains should be studied to sys-
tematically explore this parameter.
There are some limitations of the methods used in the
present study. First, the rapid bactericidal effects of some
antimicrobials occurred immediately after the compound
was added resulting in bacterial counts below limit of de-
tection at the first time point. These effects can make it
challenging to estimate the minimal growth rate at high
concentrations (ψmin) below values of −10 h
−1, as observed
for gentamicin for example. Second, the estimated bacter-
ial growth rate at high antimicrobial concentrations did
not always follow the sigmoidal four parameter model
(Fig. 4b). This was the case for the beta-lactams and in
one instance for chloramphenicol. Dose-response curves
with multiphasic features and more than one inflection
point have been observed previously and potentially indi-
cate multiple targets [39]. We therefore hypothesize that
these high concentrations induce a biological effect dis-
tinct from the primary target and removed them for the
scope of this study. Fitting a multiphasic model that could
capture this effect would make it difficult to compare the
parameters within this study and also to previous studies
using the same model [7]. Hence, the pharmacodynamic
parameters are only valid within the studied range of anti-
microbial concentrations, and benzylpenicillin, cefixime
and ceftriaxone could well exhibit stronger bactericidal ef-
fects at higher concentrations. Third, the assay time was
limited to 6 h to ensure synchronised growth for all
strains. Hence, potential regrowth at later time points and
post antibiotic effects could not be studied. Fourth, the
time-kill curves appeared to level off over time for bacteri-
cidal compounds in susceptible strains. Interestingly, this
phenomenon might represent a physiological adaptation
to those antimicrobials, often described as persister cell
formation [40–45]. This non-exponential decline makes it
difficult to estimate the growth rate with linear regression.
The clinical relevance of persister cells has been demon-
strated for chronic infections such as tuberculosis [46] and
infections caused by Staphylococcus aureus [47]. Homo-
logues to toxin-antitoxin modules involved in persister cell
formation have been described also for N. gonorrhoeae [48]
making it worthwhile considering this phenomenon in
future studies. Furthermore, the proposed time-kill method
allows the comparative evaluation of antimicrobials against
N. gonorrhoeae in vitro only and pharmacokinetic effects
were not studied.
The in vitro pharmacodynamic parameters can provide
relative comparisons across different strains and antimicro-
bials which can be extremely valuable in preclinical studies.
A novel compound can, for example, be categorised and
compared to mechanistically well-understood antibiotics
Table 1 Parameter estimates of the pharmacodynamic function for nine antimicrobials in the antimicrobial susceptible Neisseria
gonorrhoeae strain DG666
Antimicrobial Antimicrobial class кa ψmin (h
−1)a ψmax (h
−1)a zMIC (μg/ml)a MIC (μg/ml)b
Ciprofloxacin Fluoroquinolone 1.1 ± 0.1 −8.9 ± 2.2 0.7 ± 0.4 0.002 ± 0.0001 <0.004
Gentamicin Aminoglycoside 1.0 ± 0.2 −106.9 ± 140c 0.9 ± 0.07 0.2 ± 0.04 1
Spectinomycin Aminocyclitol 2.0 ± 0.6 −9.6 ± 1 0.7 ± 0.03 5 ± 0.7 4
Azithromycin Macrolide 2.5 ± 0.1 −2.2 ± 0.1 0.6 ± 0.05 0.03 ± 0.002 0.19
Benzylpenicillin β-lactam 1.1 ± 0.1 −1.6 ± 0.6 0.9 ± 0.2 0.004 ± 0.002 0.032
Ceftriaxone β-lactam 1.6 ± 0.1 −0.6 ± 0.2 0.8 ± 0.07 0.0003 ± 0.0001 <0.002
Cefixime β-lactam 1.7 ± 0.5 −0.8 ± 0.2 0.8 ± 0.1 0.0002 ± 0.0002 0.016
Chloramphenicol Chloramphenicol 1.8 ± 0.4 −0.1 ± 0.01 0.7 ± 0.2 0.5 ± 0.1 0.19
Tetracycline Tetracycline 1.0 ± 0.2 −0.2 ± 0.08 0.8 ± 0.07 0.5 ± 0.3 0.125
aEstimates are given as arithmetic means and standard deviations from two independent experiments. Parameter estimates for each individual experiment are
given in Additional file 1: Table S1
bMIC values measured with Etest in accordance with the manufacturer’s instructions
cParameter below limit of detection
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[49]. As a next step, the pharmacodynamic properties that
are obtained in vitro should be compared to data from clin-
ical PK/PD studies that include additional parameters such
as serum concentrations and half-life of the antimicrobial.
This will be important to validate whether pharmacody-
namic modeling based on in vitro data can be used to pre-
dict the outcome of different dosing strategies in vivo. For
benzylpenicillin, ceftriaxone and cefixime the time of free
antimicrobial above the MIC value should be maximised
[50–52], suggesting that multiple dose treatment would be
a rational strategy. Fluoroquinolones and aminoglycosides,
which act in a concentration dependent and bactericidal
manner, should be given as a single high dose [53]. This is
typically achieved by maximising the AUC/MIC and peak
serum concentration/MIC ratio [54–56]. Our results sug-
gest that this could be the case for ciprofloxacin, genta-
micin and spectinomycin, which were found to be
strongly bactericidal and concentration dependent.
Azithromycin has been described to be bacteriostatic in
Staphylococcus aureus, Streptococcus pneumoniae and
Haemophilus influenzae [57] but appears to act bacteri-
cidal on Pseudomonas aeruginosa [58]. The in vitro
pharmacodynamic parameters suggest that there is a
continuous gradient from bacteriostatic to bactericidal
effects and that azithromycin might fall in between
these two categories.
Conclusions
The present study shows that evaluation of the parame-
ters of a pharmacodynamic model based on in vitro
time-kill data can add valuable information beyond that
of MIC values for different antimicrobials. The quantita-
tive assessment of pharmacodynamic parameters pro-
vides a more detailed picture of antimicrobial-induced
effects on N. gonorrhoeae. The pharmacodynamic
parameters can be applied for the evaluation of new
antimicrobials and to study the effects of combining
antimicrobials against N. gonorrhoeae.
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Additional file 1: Figure S1. Growth curves for five WHO reference
strains. WHO G (A), WHO K (B), WHO L (C), WHO M (D), WHO N (E). Data
from three independent experiments are shown. CFU/ml for each time-
point are shown in circles (experiment 1), triangles (experiment 2) and
diamonds (experiment 3). A Gompertz growth model was fit to the data
from three independent experiments (solid lane, pooled data). Individual
fits from each of the experiments are shown as well in dashed lines.
Growth rates were estimated in log phase between 2 and 20 h (WHO G
= 0.75 [h-1], WHO K = 0.72 [h-1], WHO L = 0.57 [h-1], WHO M = 0.75 [h-1],
WHO N = 0.70 [h-1]). The maximal bacterial density was estimated as
upper asymptote of the Gompertz model (WHO G = 9.74*109 [CFU/ml],
WHO K = 1.32*109 [CFU/ml], WHO L = 6.57*107 [CFU/ml], WHO M =
1.32*109 [CFU/ml], WHO N = 5.32*1011 [CFU/ml]). Table S1. Parameter
estimates from nine different antimicrobials in DG666 and model based
standard errors. Table S2. Parameter estimates from ciprofloxacin in five
WHO reference strains and model based standard errors. (PDF 489 kb)
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